| Literature DB >> 33118727 |
Ilker Mercan1, Yuksel Dereli2, Cemile Topcu3, Omer Tanyeli2, Mehmet Isik2, Niyazi Gormus2, Elifnur Yildirim Ozturk4.
Abstract
OBJECTIVE: To investigate the effects of Bretschneider's histidine-tryptophan-ketoglutarate (HTK) solution and cold blood cardioplegia on systemic endothelial functions.Entities:
Keywords: Bretschneider cardioplegic solution. Von Willebrand Factor. Histidine. Heart Arrest; Induced. Potassium Chloride. Coronary Artery Bypass
Year: 2020 PMID: 33118727 PMCID: PMC7598953 DOI: 10.21470/1678-9741-2019-0327
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Fig. 1Flow-mediated dilation (FMD). NO=nitric oxide
Fig. 2“Comparison between the effects of Bretschneider’s HTK solution and cold blood cardioplegia on systemic endothelial functions in patients who undergo coronary artery bypass surgery: A prospective randomized and controlled trial” – flow diagram. ANOVA=analysis of variance; FMD=flow-mediated dilation; HTK=histidine-tryptophan-ketoglutarate
Fig. 3Diagram showing the time of taking samples and performing measurement of flow-mediated dilation (FMD) (%) values from patients included in the study.
Patients' characteristics, demographic information, and baseline data.
| Variables | Bretschneider's HTK | Cold blood | ||
|---|---|---|---|---|
| Age (mean ± SD) | (year) | 60.1±7.8 | 62.7±9.4 | 0.183 |
| Sex, n (%) | Male | 19 (76) | 21 (84) | 0.480 |
| Female | 6 (24) | 4 (16) | ||
| BMI (mean ± SD) | Kg/cm2 | 29.7±4.3 | 27.8±3.4 | 0.140 |
| LVEF (mean ± SD) | (%) | 54.0±5.7 | 53.8±5.6 | 0.771 |
| Amount of cardioplegia (mean ± SD) | (cc) | 1285±196 | 1838±344 | 0.001 |
| Medical treatments | ACE inhibitor (+) | 16 (64) | 18 (72) | 0.544 |
| Beta-blocker (+) | 23 (92) | 25 (100) | 0.149 | |
| Statin (+) | 10 (40) | 7 (28) | 0.370 | |
| Diuretic (+) | 7 (28) | 6 (24) | 0.747 | |
| Aspirin (+) | 22 (88) | 24 (96) | 0.297 | |
| Comorbid diseases | Type 2 DM (+) | 12 (48) | 13 (52) | 0.777 |
| HT (+) | 17 (68) | 12 (48) | 0.152 | |
| Hyperlipidemia (+) | 9 (36) | 12 (48) | 0.390 | |
| COPD (+) | 3 (12) | 3 (12) | 1.000 | |
| PAD (+) | 0 | 0 | 1.000 | |
| Operative features | Dose of heparin (IU) | 30.120±5.174 | 28.260±3.565 | 0.202 |
| Dose of protamine (mg) | 30.960±5.175 | 31.800±4.536 | 0.503 | |
| ACT (sec) | 478±55 | 498±57 | 0.157 | |
| Pump output ACT value | 114±6 | 112±12 | 0.259 | |
| Aortic clamp time (sec) | 54.5±15.4 | 49.7±10.9 | 0.491 | |
| Cardiopulmonary bypass time (min) | 94.2±23.7 | 93.3±21.1 | 0.719 | |
| Average heat CPB (ºC) | 31.9±0.8 | 31.7±0.5 | 0.159 | |
| Side clamp time (min) | 19.8±11.7 | 21.2±11.6 | 0.854 | |
| Heart re-beat type | 0,024 | |||
| Spontaneously | 9 (36) | 17 (68) | ||
| Fibrillated | 16 (64) | 8 (32) | ||
| Cardiac arrest time (sec) | 38.3±10.4 | 39.9±18.4 | 0.961 | |
| Intraoperative urine amount (cc) | 385±242 | 339±126 | 0.876 | |
| Intraoperative blood product use (+) | 1 (4) | 2 (8) | 0.600 | |
| Number of coronary lesions | 3.0±0.7 | 3.1±0.7 | 0.734 | |
| Number of bypass | 3.0±0.7 | 3.1±0.7 | 0.578 | |
| Use of IMA | 25 (100) | 25 (100) | 1.000 |
Mann-Whitney U test
Chi-square test
Heart re-beat type: after removal of the cross-clamp, the patients who needed defibrillation were identified as fibrillated and the group of patients who did not require defibrillation were identified as spontaneously.
ACE=angiotensin-converting enzyme; ACT=activated clotting time; BMI=body mass index; COPD=chronic obstructive pulmonary disease; CPB=cardiopulmonary bypass; DM=diabetes mellitus; HT=arterialhypertension; HTK=histidine-tryptophan-ketoglutarate; IMA=internal mammary artery; IU=international unit; LVEF=left ventricular ejection fraction; PAD=peripheral arterial disease; SD=standard deviation
Distribution of the levels of endothelial dysfunction indicators in Bretschneider's HTK and cold blood cardioplegia groups according to the time points together with the comparison of the two cardioplegia groups.
| Bretschneider's | Cold blood | F | F | F | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ADMA | T0 | 100±26 | 100±52 | 18.833 | 0.001 | Group | 2.59 | 0.115 | ADMA group | 1.886 | 014 |
| T1 | 148±34 | 157±44 | |||||||||
| T2 | 140±57 | 149±41 | |||||||||
| T3 | 128±46 | 155±51 | |||||||||
| T4 | 121±50 | 145±52 | |||||||||
| vWF | T0 | 4.0±0.6 | 4.2±0.8 | 66.287 | 0.001 | Group | 0.019 | 0.892 | vWF group | 2.79 | 0.043 |
| T1 | 5.9±1.2 | 6.3±1.2 | |||||||||
| T2 | 5.6±1.2 | 5.5±1.3 | |||||||||
| T3 | 5.1±1.1 | 4.7±1.0 | |||||||||
| T4 | 4.7±0.7 | 4.6±0.7 | |||||||||
| ET-1 | T0 | 38.7±12.5 | 36.6±5.2 | 99.115 | 0.001 | Group | 10.923 | 0.002 | ET-1 group | 8.957 | 0.001 |
| T1 | 59.0±13.1 | 68.4±6.2 | |||||||||
| T2 | 56.5±14.0 | 66.6±6.4 | |||||||||
| T3 | 49.4±15.0 | 63.5±7.8 | |||||||||
| T4 | 45.5±11.0 | 53.5±10.2 | |||||||||
| Lactate | T0 | 1.4±0.4 | 1.4±0.4 | 25.32 | 0.001 | Group | 1.67 | 0.202 | Lactate group | 1.23 | 0.301 |
| T1 | 2.5±0.5 | 2.1±1.1 | |||||||||
| T2 | 1.9±0.6 | 1.8±0.6 | |||||||||
| T3 | 1.7±0.5 | 1.4±0.4 | |||||||||
| T4 | 1.5±0.4 | 1.5±0.5 | |||||||||
| FMD | T0 | 6.20±0,92 | 6.10±1.14 | 46.083 | 0.001 | Group | 4.326 | 0.043 | FMD group | 6.58 | 0.008 |
| T2 | 5.57±0.79 | 4.68±1.02 | |||||||||
| T4 | 5.74±0.81 | 5.27±0.89 |
Two-way analysis of variance for mixed measured
ADMA=asymmetric dimethylarginine; ET-1=endothelin-1; FMD=flow-mediated dilation; HTK=histidine-tryptophan-ketoglutarate; vWF=von Willebrand factor
Fig. 4Distribution of the flow-mediated dilation levels of the study groups according to the time points (%). HTK = Histidine-tryptophan-ketoglutarate
Postoperative complications.
| Bretschneider's HTK | Cold blood | |||
|---|---|---|---|---|
| Total complications | n (%) | 11 (44) | 13 (52) | 0.571 |
| Pulmonary | n (%) | 7 (28) | 7 (28) | 1.000 |
| Antibiotic revision | n (%) | 3 (12) | 8 (32) | 0.088 |
| Arrhythmia | n (%) | 2 (8) | 5 (20) | 0.221 |
| Neurological | n (%) | 2 (8) | 2 (8) | 1.000 |
| Renal | n (%) | 2 (8) | 2 (8) | 1.000 |
| Gastrointestinal | n (%) | 1 (4) | 0 | 0.312 |
HTK=histidine-tryptophan-ketoglutarate
Patient follow-up in the postoperative period.
| Bretschneider's HTK | Cold blood | |||
|---|---|---|---|---|
| Amount of drainage | (cc) | 1027±362 | 1123±450 | 0.600 |
| Amount of blood used | unit | 1.7±1.1 | 1.7±1.4 | 0.819 |
| Inotropic need and dosage | mcg/kg/day | 0.039±0.058 | 0.040±0.053 | 0.460 |
| Extubation time | (hour) | 9.6±2.7 | 10.8±4.2 | 0.335 |
| ICU stay | (hour) | 42.8±17.4 | 46.4±19.7 | 0.366 |
HTK=histidine-tryptophan-ketoglutarate; ICU=ıntensive care unit
| Abbreviations, acronyms & symbols | ||||
|---|---|---|---|---|
|
|
|
|
|
|
| Authors' roles & responsibilities | |
|---|---|
| IM | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |